Behavioral symptoms and treatment challenges for patients living with dementia: Hospice clinician and caregiver perspectives
Open Access
- 16 December 2024
- journal article
- research article
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 73 (4) , 1094-1104
Abstract
Introduction: Dementia affects one in three older adults over age 85 and individuals with dementia constitute the fastest growing population of patients entering hospice care. While cognitive impairment is the hallmark of dementia, behavioral symptoms are reported in nearly all patients with advanced dementia, contributing to both the complexity of end‐of‐life care and caregiver burden. Methods: This qualitative study involved semi‐structured interviews with prescribing hospice clinicians and caregivers of patients living with dementia who previously received hospice services. Interviews included questions regarding common behavioral symptoms observed at end of life, side effects of benzodiazepine and antipsychotic medications, perceived effectiveness of medications used, and non‐pharmacologic treatment strategies. Data from audio‐recorded sessions were transcribed, coded to identify relevant concepts, and reduced to determine major themes. Results: A total of 23 hospice clinicians and 20 family caregivers participated in interviews. Agitation, including physical and verbal aggression, irritability, and anger, was identified as the most concerning behavioral symptom of dementia at end of life; when discussing agitation, clinicians focused on the safety of the patient living with dementia and others, while caregivers were concerned because they perceived it as a change in personality of their loved one. When using antipsychotics and benzodiazepines to address behavioral symptoms, caregivers viewed sedation as a concerning side effect, while clinicians were less concerned and noted this as an anticipated outcome of treatment. Overall, family caregivers perceived medications as more effective than clinicians. Finally, non‐pharmacologic interventions are generally preferred over pharmacologic treatments, but were reported as difficult to implement. Conclusions: Study findings can help to inform dialogue between hospice clinicians and caregivers regarding anticipated behavioral changes, as well as risks, benefits, and limitations of medication treatment options for behavioral symptom management. Further work is needed to understand the appropriate level of use of psychotropic medications for end‐of‐life dementia care.Keywords
Funding Information
- National Institute on Aging (K23AG066864)
This publication has 29 references indexed in Scilit:
- Hospice Enrollment and Central Nervous System–Active Medication Prescribing to Medicare Decedents with DementiaJAMA Psychiatry, 2024
- Characteristics of Emergency Department Visits Among Older Adults With DementiaJAMA Neurology, 2023
- Factors Associated With Benzodiazepine and Antipsychotic Prescribing in Hospice: A Qualitative Study of Hospice PrescribersJournal of the American Medical Directors Association, 2023
- Impact of agitation in long‐term care residents with dementia in the United StatesInternational Journal of Geriatric Psychiatry, 2021
- Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020–2060)Alzheimer's & Dementia, 2021
- Practices, challenges, and opportunities when addressing the palliative care needs of people living with dementia: Specialty memory care provider perspectivesAlzheimer's & Dementia: Translational Research & Clinical Interventions, 2021
- Drug therapy for delirium in terminally ill adultsCochrane Database of Systematic Reviews, 2020
- Using electronic health records to estimate the prevalence of agitation in Alzheimer disease/dementiaInternational Journal of Geriatric Psychiatry, 2018
- Efficacy of Oral Risperidone, Haloperidol, or Placebo for Symptoms of Delirium Among Patients in Palliative CareJAMA Internal Medicine, 2017
- Caregiving as a Risk Factor for MortalityJAMA, 1999